Can I administer Menactra (meningococcal conjugate vaccine) and Hib (Haemophilus influenzae type b) vaccine on the same day?

Yes, Menactra and Hib Vaccine Can Be Given on the Same Day

Yes, you can safely administer Menactra (meningococcal conjugate vaccine) and Hib vaccine on the same day, using different syringes at separate injection sites. 1

Key Administration Requirements

The FDA label for Menactra explicitly permits concomitant administration with other vaccines, including Hib-containing vaccines, with these critical stipulations 1:

• Use separate syringes - never mix vaccines in the same syringe
• Use different injection sites - administer at anatomically distinct locations
• Give simultaneously or space appropriately based on age-specific considerations below

Age-Specific Considerations

Children Under 2 Years

Menactra has been studied and co-administered with various vaccines in children younger than 2 years, including PCV7, MMR, varicella, MMRV, and hepatitis A 1. Research confirms that Hib-containing vaccines can be safely co-administered with meningococcal conjugate vaccines in infants as young as 2 months 2, 3.

Children 4-6 Years

Important timing consideration: When administering to children aged 4-6 years who are also receiving DTaP (DAPTACEL), the FDA label recommends 1:

• Preferred: Give Menactra and DTaP simultaneously, OR
• Alternative: Give Menactra BEFORE DTaP
• Avoid: Giving Menactra one month AFTER DTaP, as this reduces meningococcal antibody responses

This timing concern applies specifically to DTaP interaction and does not prohibit same-day Hib administration.

Immunogenicity Evidence

Multiple studies demonstrate that co-administration maintains robust immune responses:

• A 2019 randomized trial showed that Hib-MenCY conjugate vaccine co-administered with rotavirus, hepatitis A, and pneumococcal vaccines induced robust immune responses without interference 2
• A 2013 study confirmed that combined Hib-MenC vaccines were immunogenic when co-administered with other routine vaccines 3
• A 2002 Canadian trial demonstrated that meningococcal C conjugate vaccine given with DTaP-IPV-Hib achieved 99-100% protective antibody levels 4

Safety Profile

The safety profile for concomitant administration is well-established 1:

• Local reactions may occur at each injection site independently
• Systemic reactions (headache, fatigue) are comparable to single vaccine administration
• No increased risk of serious adverse events with co-administration

Common Pitfalls to Avoid

1. Never mix vaccines in the same syringe - this is explicitly contraindicated 1
2. Don't delay Menactra if DTaP was recently given - if DTaP was administered within the past month in a 4-6 year old, you may see reduced meningococcal response, but this doesn't prohibit administration if indicated
3. Document injection sites clearly - helps identify which vaccine caused any local reactions